OncoMatch/Clinical Trials/NCT07202052
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Is NCT07202052 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Intravenous immunoglobulin and Intravenous immunoglobulin (IVIG) for myeloma.
Treatment: Intravenous immunoglobulin · Trimethoprim / Sulfamethoxazole · Amoxicillin clavulanic acid · Intravenous immunoglobulin (IVIG) — This is an adaptive platform study to find out how safe and effective different strategies are in comparison to each other, for preventing infection in patients with blood cancers. It is a comparison between Immunoglobulin and antibiotics use.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify